Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLEGRA6: Sublingual Grass Pollen Immunotherapy
NCT00623701Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Mar 2008
- Primary completion
- Oct 2011
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of allerslit forte in allergic rhinoconjunctivitis (ARC), sponsored by Allergopharma. Started Mar 2008; status: completed.
02
Drugs
allerslit forte
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00623701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623701.